CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 66 enrolled
Drug / intervention
minocycline hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01053156
NCT01053156N/ACompleted
CompareCT.gov

Randomized Double-Blind Controlled Cross Over Trial of Minocycline in Children With Fragile X Syndrome

University of California, Davis·interventional·Posted Jan 21, 2010·Updated May 30, 2017

In Brief

A clinical study evaluating minocycline hydrochloride and Placebo for Fragile X Syndrome. Completed, enrolled 66 participants across 1 site.

Detailed Summary

This is a single center study at the UC Davis MIND Institute in patients age 3.5-16 years of age with fragile X syndrome (FXS), funded by a National Fragile X Foundation Grant. It is a controlled trial of minocycline, an antibiotic commonly used in children for infection or for treatment of neurodegenerative disorders. We are investigating its use in FXS because it lowers matrix metalloproteinase 9 (MMP9) levels, which are high in FXS, and it also strengthens brain connections in the animal models of FXS. We hypothesize that minocycline will likely be helpful for language, behavior and/or cognition in fragile X patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFragile X Syndrome
CountriesUnited States
CollaboratorsThe National Fragile X Foundation

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 21, 2010
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.4 years ago

Interventions

minocycline hydrochloridedrug

Minocycline hydrochloride dosed orally once a day for 3 months.

Placebodrug

Placebo will be given daily for 3 months.